Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FHCT002
- Development stage
- Preclinical
- Lead developer
- FullHope Biomedical
- Modality
- Cell Therapies
01
Overview
FHCT002 is an autologous cell therapy candidate being developed by FullHope Biomedical for the treatment of autoimmune diseases. The therapy is part of a personalized medicine approach that leverages the company's proprietary immunoprofiling platform to analyze patient-specific immune profiles and identify optimal cell therapy interventions. FHCT002 is currently in clinical development in Taiwan, with trials conducted in collaboration with institutions such as National Taiwan University Hospital and Taipei Veterans General Hospital. While the specific cell type and molecular targets remain proprietary, the product is protected by patents in Taiwan and China.
Beyond the preview
Go deeper on FHCT002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FHCT002.